Cardiol Therapeutics Inc CRDL.TO is expected to show no change in quarterly revenue when it reports results on April 10 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Cardiol Therapeutics Inc is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 8.8% in the last three months.
Wall Street's median 12-month price target for Cardiol Therapeutics Inc is $9.00, above its last closing price of $0.85.
This summary was machine generated April 8 at 20:12 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)